Literature DB >> 23761029

[DRESS syndrome. Rare and potentially lethal allergic reaction to carbamazepine - a case report].

A Werber1, M Schiltenwolf, A Barié.   

Abstract

A 64-year-old man with chronic low back pain had been treated with tramadol, meloxicam and metamizole for several years. Due to additional neuropathic pain in the lower extremities, the medication was complemented with carbamazepine. After 5 weeks of treatment, the patient developed maculopapulose exanthema and fever, followed by hepatitis, leukocytosis and eosinophilia. The patient was diagnosed with so-called DRESS (drug rash with eosinophilia and systemic symptoms) syndrome, a severe anaphylactic reaction to carbamazepine treatment. Immunosuppressive therapy was complicated by an additional septic reaction. After recovery, the patient was referred to our clinic for a multimodal pain therapy. Fear, depressive episodes and fear-avoidance behavior were additional social factors responsible for the chronic pain syndrome of the patient. The previously diagnosed neuropathic pain syndrome cannot be verified. After appropriate modification of therapy, the patient's pain perception was significantly reduced, allowing for complete withdrawal of pain-relieving medication. This case report illustrates that merely pharmacological treatment of chronic pain syndromes bears only little prospect of success but increased risk of side effects.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23761029     DOI: 10.1007/s00482-013-1328-8

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  15 in total

Review 1.  Pharmacologic management of neuropathic pain: evidence-based recommendations.

Authors:  Robert H Dworkin; Alec B O'Connor; Miroslav Backonja; John T Farrar; Nanna B Finnerup; Troels S Jensen; Eija A Kalso; John D Loeser; Christine Miaskowski; Turo J Nurmikko; Russell K Portenoy; Andrew S C Rice; Brett R Stacey; Rolf-Detlef Treede; Dennis C Turk; Mark S Wallace
Journal:  Pain       Date:  2007-10-24       Impact factor: 6.961

2.  [Chronified back pain].

Authors:  Andreas Werber; Marcus Schiltenwolf
Journal:  MMW Fortschr Med       Date:  2012-06-21

Review 3.  Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.

Authors:  S R Knowles; L E Shapiro; N H Shear
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

4.  [Chronic lower back pain].

Authors:  A Werber; M Schiltenwolf
Journal:  Nervenarzt       Date:  2012-02       Impact factor: 1.214

5.  Logic, truth and language in concepts of pain.

Authors:  H Merskey
Journal:  Qual Life Res       Date:  1994-12       Impact factor: 4.147

6.  Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values.

Authors:  R Rolke; R Baron; C Maier; T R Tölle; - D R Treede; A Beyer; A Binder; N Birbaumer; F Birklein; I C Bötefür; S Braune; H Flor; V Huge; R Klug; G B Landwehrmeyer; W Magerl; C Maihöfner; C Rolko; C Schaub; A Scherens; T Sprenger; M Valet; B Wasserka
Journal:  Pain       Date:  2006-05-11       Impact factor: 6.961

Review 7.  Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses.

Authors:  Tetsuo Shiohara; Miyuki Inaoka; Yoko Kano
Journal:  Allergol Int       Date:  2006-03       Impact factor: 5.836

Review 8.  A treatment algorithm for neuropathic pain.

Authors:  Mike Namaka; Colin R Gramlich; Dana Ruhlen; Maria Melanson; Ian Sutton; Joanne Major
Journal:  Clin Ther       Date:  2004-07       Impact factor: 3.393

Review 9.  Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update.

Authors:  S Tas; T Simonart
Journal:  Dermatology       Date:  2003       Impact factor: 5.366

10.  Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation.

Authors:  M Mennicke; A Zawodniak; M Keller; L Wilkens; N Yawalkar; F Stickel; A Keogh; D Inderbitzin; D Candinas; W J Pichler
Journal:  Am J Transplant       Date:  2009-09       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.